Symposium – Dx Toxicology: Strategies for Success in Discovery and Development Attrition due to safety/toxicity remains a challenge in drug discovery and development. Strategies to improve success focus on asking the right questions at the right time around Target, Chemistry and Patient with an emphasis on translation of data [...]
Cost Effective Study Monitoring Services at Non-Clinical CROs in North America Steve Snyder is partnering with ApconiX to provide cost-effective study monitoring services at nonclinical CROs in North America. Steve is a US-based independent consultant who currently provides study monitoring services for clients ranging from global pharmaceutical companies to [...]
ApconiX Opens a New Office in Sweden ApconiX is excited to announce the opening of our new office in Sweden. The subsidiary ApconiX AB will be located at AstraZeneca’s BioVentureHub in Gothenburg. ApconiX was formed by Dr Richard Knight, Dr Michael Morton and Professor Ruth Roberts in 2015 and [...]
Professor Ruth Roberts Hosts ATS Meeting Professor Ruth Roberts was elected President of the Academy of Toxicology Sciences in June 2018 and holds the position until June 2019. She will be hosting the ATS Annual Business Meeting and Reception at SOT on Tuesday, March 12 where she will be [...]
ApconiX Welcomes Dr Steffen Ernst ApconiX is delighted to welcome Dr Steffen Ernst to our team, as the company begins its international expansion with the formation of its Swedish subsidiary, ApconiX AB. Steffen has worked in preclinical and clinical safety for over 20 years with Hoechst-Schering, Boehringer-Ingelheim, AstraZeneca, Pfizer [...]
Study monitoring – What is it and why is it important to drug discovery projects? Guy Healing, Senior Toxicologist at ApconiX is interviewed by Jon Clements of Metamorphic PR Pharma companies need to ensure their drugs are safe but also that they work. In drug development, this requires numerous studies to [...]
ApconiX Welcomes Steve Snyder ApconiX is delighted to welcome Steve Snyder to the team. Steve joins the nonclinical study monitoring team and is based in Florida in the United States. Having worked at Wyeth, Eli Lilly, McNeil Pharmaceutical and Charles River, Steve has a wealth of experience in preclinical [...]
ApconiX Welcomes Dr Bjorn Dahl ApconiX is delighted to welcome Dr Björn Dahl to the team, who joins our new Swedish office at AstraZeneca’s BioVentureHub in Gothenburg. Björn is a highly respected and experienced toxicologist, having been the co-chair of the European Federation Pharmaceutical Industry Association (EFPIA) Preclinical Development [...]
ApconiX are delighted to learn that the BTS Executive Committee has elected Professor Ruth Roberts as Honorary Fellow of the British Toxicology Society (hon FBTS) in recognition of her outstanding contribution to the science and profession of Toxicology, including to the BTS. Ruth commented “It’s such an honour to be recognised in this way by [...]
Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity Abstract Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been associated with [...]
